Reciprocal regulation of fibroblast–macrophage equilibrium governs skin integrity Nature Immunology - Turley, Buechler and colleagues show that dermatopontin-expressing fibroblasts provide CSF1 to form a supportive niche for skin-resident macrophages. This interaction is...

So glad to share our new work in #NatureImmunology highlighting that #fibroblast-#macrophage dialogue is a cornerstone of skin integrity in health and disease. Big congrats to all the authors at #UofT and #Genentech for their tireless efforts. Looking for #PDs to continue this work~ rdcu.be/e50PJ

Deal takeaways - Strong platform validation for Shengyin’s RNAi chemistry and delivery technologies - Meaningful non-dilutive capital with retained upside via milestones and royalties - Genentech assumes late-stage development and commercialization risk, a classic risk-sharing structure - Signals continued Big Pharma appetite for RNAi assets, especially platform-driven programs From an investment perspective, this deal highlights how differentiated RNA platforms can command premium economics even at early clinical stages—and how large pharma is selectively re-entering RNAi with improved delivery solutions.

RNAi deal worth watching from an investment lens
SanegeneBio announced a global licensing agreement with Genentech (罗氏公司 Group) for an RNAi therapeutic, featuring $200M upfront, up to $1.5B in milestones, plus tiered royalties.
#BiotechInvesting #RNAi #LicensingDeals #PharmaBD #Roche #Genentech

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies SanegeneBio has entered into a significant global partnership with Genentech to develop RNAi therapeutics, receiving $200 million upfront and potential earnings up to $1.5 billion.

SanegeneBio Signs Major Global RNAi Licensing Deal with Genentech for Groundbreaking Therapies #United_States #Boston #Genentech #RNAi_Therapeutics #SanegeneBio

38. We understand disease and treat it For our thirty-eighth episode, we're exploring a company that has been at the forefront of the fight against cancer for decades. A company that built its empire on a unique, two-pillar strategy that is perfectly suited for the future of healthcare. They don't just want to sell you the cure; they want to sell the test that tells you if the cure will work. It’s a story of visionary acquisitions and world-class science. We are talking about the Swiss giant... Roche. When you hear the name Roche ($RHHBY), you think of a global pharmaceutical powerhouse, a Swiss giant renowned for its leadership in developing cancer treatments. For decades, it has been a defensive cornerstone in portfolios, known for its deep scientific expertise and a vast portfolio of life-saving medicines. But the real story and strategic advantage of Roche lie in its unique dual structure. It is a world leader in not just pharmaceuticals but also in-vitro diagnostics. This powerful combination allows Roche to champion "personalized healthcare"—they can develop a diagnostic test to identify which patients will benefit most from a specific drug, and then provide that targeted therapy. This integrated model creates a formidable competitive moat. However, like all pharma giants, Roche is in a constant race against the patent cliff, with blockbuster drugs facing biosimilar competition. We're analyzing the data to see if Roche's synergistic approach and powerful R&D pipeline are enough to outrun patent expirations and diagnose a healthy future for investors.

📣 New Podcast! "38. We understand disease and treat it" on @Spreaker #biotech #defensive #diagnostics #dividend #drugs #finance #genentech #healthcare #innovation #investing #oncology #patents #personalized #pharma #pipeline #portfolio #rhhby #roche #stock #swiss

2) .. inşaat alanlarında 2 binden fazla doğrudan istihdam yaratılması bekleniyor. Yatırım, Genentech’in yeni nesil metabolik tedaviler üretme kapasitesini artırmayı ve Roche’un ABD’deki uzun vadeli üretim stratejisini güçlendirmeyi amaçlıyor. #roche #genentech

We're no longer alone! A few months after our preprint, another study appeared from #Genentech reporting no MRI brain volume or behaviour differences in adult C3aR1 KOs + their data contradicts another accepted C3aR1 neuroinflammation phenotype. Check it out: www.biorxiv.org/content/10.1...

NEW WORKSHOP "Top-Down, Intact, and Native Mass Spectrometry in Biopharmaceutical Characterization" Feb.12, 2026. Speakers from #AstraZeneca, #Novartis, #Pfizer, #Genentech, #Sanofi, #JnJ, #Lilly and #NIBRT share stories and perspectives. > ctdp.org/biopharma-wo... #ADCs #mAbs #BsAbs #TsAbs #AAVs

As year-end nears, pharma groups plump up their pipelines Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

#BristolMyersSquibb #Sanofi #Pfizer #Roche #YarrowBioscience #RandDpipelines #HarbourBioMed #Genentech #AI #CarisLifeSciences #CarisDiscovery #ADEL #phase1testing #DrenBio #drugdiscovery #immunology #oncology #rheumatology #Gravesdisease #GeneSciencePharma #GenSci
zurl.co/Kyjjn

Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech - OncoDaily Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech / Brian J. Brille, cancer, Caris Discovery, Caris Life Sciences,

Caris Discovery Entered Into a Multi-Year Collaboration and License Agreement with Genentech

oncodaily.com/voices/caris...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CarisDiscovery #Genentech

Caris Life Sciences Teams Up with Genentech for Cancer Research Breakthroughs Caris Life Sciences has partnered with Genentech to explore new cancer treatment targets, aiming to enhance precision medicine and address unmet clinical needs.

Caris Life Sciences Teams Up with Genentech for Cancer Research Breakthroughs #United_States #Cancer_Research #Caris_Life_Sciences #Irving #Genentech

Genentech: Press Releases | Monday, Dec 8, 2025 Discover the latest news about our company, our products, our policies, and our people.

⚡️ #Genentech présente des données de #Lunsumio montrant un potentiel dans les #Lymphomes 🩸 indolents et agressifs.

Le Lunsumio avec la #Lénalidomide 💊, offre un traitement efficace pour le lymphome folliculaire R/R, basé l’étude de phase III #CELESTIMO

www.gene.com/media/press-...

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Gilead #Genentech

Genentech: Press Releases | Monday, Nov 17, 2025 Discover the latest news about our company, our products, our policies, and our people.

🔴 #Breaking : #Giredestrant 🧬 de #Genentech devient la première #SERD orale à montrer une survie invasive sans maladie supérieure dans le #CancerDuSein précoce.

👉 Résultats positifs de phase III de l’étude #LidERA

#BreastCancer 🦀 #ESMO25
www.gene.com/media/press-...

34-35 PHARMA - Time capsule Time capsule. The ten groundbreaking drugs shaping 2025 and the future

#Vertex #Cysticfibrosis #AstraZeneca #DaiichiSankyo #lungcancer #breastcancer #painmanagement #Alnylam #Sanofi #Haemophilia #Genentech #Roche #MS #MSD #Hypercholesterolemia #Pfizer #InnoventBiologics #EliLilly #Obesity #type2diabetes #GSK #eosinophilicasthma #meningitisvaccine
zurl.co/bzBzK

Nona: A unifying multimodal masking framework for functional genomics The non-coding genome encodes complex regulatory logic that orchestrates gene expression and cell identity. While machine learning models for functional genomics have advanced our understanding of the...

This would not have been possible without my amazing colleagues from BRAID #Genentech: Gökcen Ehsan Alex @johahi.bsky.social Nate @avantikalal.bsky.social Tommaso Hector Gabriele

You can find the preprint here: www.biorxiv.org/content/10.1...

12/

Genentech: Press Releases | Sunday, Nov 9, 2025 Discover the latest news about our company, our products, our policies, and our people.

Le #Fénébrutinib de #Genentech montre des résultats positifs sans précédent en phase III en tant que premier et seul inhibiteur potentiel de la #BTK dans la #ScléroseEnPlaques ( #RMS) progressive récurrente et primaire
www.gene.com/media/press-...

Meet the keynote speakers for the 2025 scverse conference!

John Marioni, Head of Computation at Genentech Research and Early Development and former head of EBI
🧵

#scverse #scverse2025 #AI #DrugDevelopment #MachineLearning #ComputationalBiology #Biotech #Pharma #Genentech

🌟 Thank You to Our Gold Sponsor: Genentech! 🌟

We're delighted to recognize Genentech as a Gold Sponsor of scverse conference 2025! 🏆

#scverse2025 #ComputationalBiology #SingleCell #DrugDiscovery #Genentech #SpatialOmics #Bioinformatics #Biotechnology

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward The FDA has approved Gazyva® for lupus nephritis in adults, illustrating an important advancement in treatment options against this debilitating condition.

FDA Greenlights Gazyva® for Lupus Nephritis Treatment: A Major Step Forward #USA #Washington #Lupus_Nephritis #Genentech #GAZYVA

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment The Lupus Research Alliance expresses gratitude for the FDA's approval of Gazyva, marking a significant advancement in lupus nephritis management.

Lupus Research Alliance Celebrates FDA Approval of Gazyva for Lupus Nephritis Treatment #USA #New_York #Lupus_Nephritis #Genentech #GAZYVA

Welcome prospective #SFSU students to DISCOVER SFSU!!! We are so happy to have you join us!! A shout out to @sfstatebio.bsky.social alumna #Leslie_Valencia #Genentech being highlighted in today’s program!👏🏽👏🏽👏🏽 @calstate.bsky.social #SFSU_COSE

Genentech: Press Releases | Sunday, Sep 21, 2025 Discover the latest news about our company, our products, our policies, and our people.

Des résultats positifs de phase III montrent que le #Giredestrant 🧬 de #Genentech 🇺🇸, membre du groupe #Roche 🇨🇭 (SIX : RO, ROG ; OTCQX : RHHBY), a considérablement amélioré la survie sans progression dans le #CancerDuSein avancé RE positif
www.gene.com/media/press-...

OMass attracts $420m Roche wager on IBD programme UK biotech OMass has revealed its first major pharma partnership, with Roche paying $20m upfront for an inflammatory bowel disease programme.

UK biotech #OMassTherapeutics has revealed its first major pharma #partnership, with Roche's #Genentech unit paying $20 million upfront to tap into its expertise and find small-molecule therapies for inflammatory bowel disease (#IBD).

Roche breaks ground on US manufacturing facility Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50bn US investment programme.

Roche's #Genentech unit has started work on a $700 million #manufacturing facility in North Carolina, part of a promised $50 billion #investment in the #US.

pharmaphorum.com/news/roche-b...

Meet the keynote speakers for the 2025 scverse conference!
John Marioni, Head of Computation at Genentech Research and Early Development
🧵

@genentech.bsky.social

#scverse #scverse2025 #AI #DrugDevelopment #MachineLearning #ComputationalBiology #Biotech #Genentech #Stanford

📌 Más recursos: cancergrace.org/forum
Agradecemos a nuestros patrocinadores por hacerlo posible: #janssen #takeda #genentech #bms #daiichisankyo

Advanced Conformal Prediction: Reliable Uncertainty Quantification for Real-World Machine Learning (Preorder / Early Access) 🚀 Advanced Conformal Prediction: Practical Uncertainty Quantification for Real-World ML 🚀Preorder / Early Access – Chapters released progressivelyFull book priced at over $80+ USD.Are you ready to take your machine learning models to the next level? Move beyond basic predictions and master advanced techniques for quantifying and managing uncertainty with confidence.In "Advanced Conformal Prediction," you'll dive deep into sophisticated methods designed to enhance reliability and decision-making in real-world AI applications. This comprehensive guide equips you with practical skills and cutting-edge tools, empowering you to confidently deploy machine learning solutions in high-stakes environments.Whether you're a data scientist, engineer, researcher, or practitioner, this book will become your essential resource for ensuring the trustworthiness of your AI models.📖 What's Inside: Advanced methods for uncertainty quantification Practical insights for real-world AI deployment Techniques for improving model reliability Join the journey and transform your approach to AI uncertainty today!🌟 Perfect for: Data Scientists and ML Engineers AI Researchers Professionals deploying ML in critical industries Secure your copy now and revolutionize how you manage uncertainty in machine learning!

valeman.gumroad.com/...

📄 Genentech paper: arxiv.org/abs/2405.0...

#MachineLearning #ConformalPrediction #UncertaintyQuantification #ICML2024 #Genentech #STEM #LearnLikeAPro

Bay Area Biotech Bulletin – August 2025 Edition

#biotech #layoffs #vcfunding #lifesciences #bayarea #biotechnews #fda #genentech #startups #investment #biotechjobs #biotechbulletin #biotechtrends #biopharma #medtech #drugdevelopment #schizophrenia #manufacturing #biotechindustry

Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer - Orionis Biosciences Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for o...

Sharing news today of another #Genentech collaboration! Very proud and excited to be shaping the future of medicine with the #Orionisbio Team 💪orionisbio.com/2025/05/genentech-collab...

Autonome KI-Agenten revolutionieren die Krebsforschung: TU Dresden & #Genentech zeigt in Nature Cancer, wie KI künftig Experimente plant, Daten auswertet & klinische Studien vorbereitet – mehr Zeit für Kreativität & Strategie. #KI #Krebsforschung
doi.org/10.1038/s430...